

Symptom records for your next visit.

Product and business brief · 10 October 2026

Yamma is an unreleased Android personal health-record prototype. Our first audience is Korean-speaking adults who want to organize changes in their symptoms before a follow-up visit.

The task is concrete: remember when something started, keep a record of changes, and bring the details and questions you want to discuss. Yamma starts with records that the person enters and reviews.

The current prototype

Step	Implemented scope
Record and confirm	Enter symptom details and review them before saving.
Keep the record	Save confirmed entries in an encrypted database on the Android device.
Return to the diary	View entries by recording date and body area, with the highest recorded intensity for each date, area, and symptom type.

An onset date describes when a symptom started. A recording date describes when the entry was made. The current diary groups entries by recording date. A blank or unconfirmed detail does not mean that it is absent.

The planned visit journey

We plan to extend those records into factual visit summaries, care navigation, prescription review, medication records, and a health calendar. These workflows and their redesigned screens are product plans. The six public images are **UI design concepts**.

Yamma organizes personal records. It does not provide diagnoses or prescriptions.

Explore the product: flu-bio.com/product/

Check development status: flu-bio.com/build/

A free record-keeping core, with an optional Visit Pack.

Pre-launch plan · Pricing hypothesis

We propose a direct-to-consumer model: keep everyday recording accessible, and test whether people will pay for tools that assemble a visit packet from records they have reviewed.

Proposed offer	What it would include
Core - free	Manual symptom records, local storage, diary access, and basic portable record export. Basic export is planned.
Visit Pack - KRW 4,900 for 30 days	Choose records from a date range, reuse a visit preparation layout, and assemble a printable packet. These paid workflows are planned.

The proposed pass would have **no automatic renewal**. Expiry would leave core records and files already exported with the user. We would charge for preparing and organizing a packet, not for access to a diagnosis or medical advice.

Why a 30-day pass?

Visit preparation may be occasional. A short, optional pass ties the payment to that task without assuming that everyone needs an ongoing subscription. KRW 4,900 is an initial price to test with the intended audience. It is not a validated market price or a purchase offer.

We would first compare the value of a blank worksheet and basic export with the proposed packet tools. If people can complete the task just as well with the free options, the paid scope needs to change before it is built or sold.

An illustrative revenue calculation

Assumptions, not reported results or a forecast: 1,000 monthly active users × 5% buying one pass in that month × KRW 4,900 = **KRW 245,000 in gross receipts for that month.**

This is before taxes, platform and payment fees, refunds, and operating costs. A non-renewing pass does not create contracted monthly recurring revenue.

Read the proposed plan: flu-bio.com/plans/

Discuss the workflow or price: hello@flu-bio.com

What we plan to test next

Product checks, development evaluation and project status

Question	Planned work	What we would record
Can people keep a clear record?	Small usability sessions using prepared examples.	Task completion, correction errors, and whether onset and recording dates are understood.
Does a visit packet help?	Compare the blank sheet, basic export, and proposed packet layout.	Time to find a recorded detail, missing information, and preference for the next visit.
Is the paid scope worth the price?	Discuss the 30-day pass with the first audience.	Reasons to pay or decline, desired frequency, and which feature changes the decision.

These are product and usability checks. They would not establish clinical effectiveness. Release timing will follow implementation and testing; this brief does not announce a launch date.

Claude in our development plan

Our Claude plan covers coding, test design, and a separate evaluation of Korean structured extraction and factual summaries. The evaluation would compare candidate outputs with authored development cases and check schema validity, omitted or added facts, latency, and cost.

The current manual-entry path does not require a Claude call. The planned production direction uses self-hosted open models in South Korea. The separate Claude evaluation is not a deployed clinical integration or a completed benchmark.

Read the evaluation plan: flu-bio.com/claude/

Founder and project status

Woojin Jung (정우진) is a medical student at Chungnam National University College of Medicine and is planning and developing Yamma. Project planning began in **May 2026**.

FluBioscience is the business brand behind the project. The project is currently unincorporated, with incorporation planned after the app’s official launch. It has not raised outside funding, as stated by the founder.

Leased office: 160, Techno 2-ro, Yuseong-gu, Daejeon, South Korea.

Try the blank visit preparation sheet: flu-bio.com/resources/

Contact: hello@flu-bio.com · flu-bio.com/about/